Axitinib is a medication that stops cancer cell growth by depriving the cancer cell of the nutrients and oxygen that it needs. Axitinib is used to treat advanced renal cell carcinoma (RCC), which is a type of kidney cancer that has spread within or beyond the kidney. Axitinib has been approved for the treatment of RCC as either a first treatment option or a second treatment option. It is used as a first treatment option for RCC when combined with a medication that reactivates the immune system (immunotherapy), either avelumab or pembrolizumab. If the advanced RCC starts growing again it can be used as a second treatment option where it is taken by itself. It is essential to conduct studies to assess how well the drug works and whether it has any side effects in order to understand whether it is safe to give to people.This Plain Language Summary of Publication article in Future Oncology looks at axitinib treatment in people with advanced renal cell carcinoma (RCC). Advanced RCC is a type of kidney cancer that has spread within/beyond the kidney. Axitinib is a medication that has been approved to treat RRC as either a first/second treatment option. This summary describes the results of five studies, in particular looking at how long side effects last after people stopped taking axitinib temporarily.

You can read the full plain language article here.

The original article on which this summary is based on is called ‘Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma’ and was published in Clinical Genitourinary Cancer. 

Read the original article here.